Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T17:22:52.437Z.
Calculation as of: 2026-10-06T17:22:52.437Z.
Quote observation: 2026-10-06T17:19:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2d3a9198413857e44d8ff08287218970dc762668c083e85858692cc7a401d48f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Neonc Technologies Holdings, Inc.
Market Cap
$77.80M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$77.53M
PS Ratio
1107.54
TTM Avg
1529.19
3Y Avg
1390.50
5Y Avg
1326.39
Market Cap
$78.76M
PS Ratio
N/A
TTM Avg
596.04
3Y Avg
341.95
5Y Avg
283.35
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Neonc Technologies Holdings, Inc. (NTHI) | $77.80M | N/A | N/A | N/A | N/A |
| Sera Prognostics, Inc. (SERA)vs › | $77.53M | 1107.54 | 1529.19 | 1390.50 | 1326.39 |
| Pulmonx Corporation (LUNG)vs › | $77.51M | 0.89 | 0.79 | 2.77 | 7.10 |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $78.76M | N/A | 596.04 | 341.95 | 283.35 |
| Hyperfine, Inc. (HYPR)vs › | $76.64M | 4.63 | 8.05 | 7.13 | 57.60 |
| SkinHealth Systems Inc. (SKIN)vs › | $76.14M | 0.26 | 0.44 | 0.68 | 3.19 |
| Nutriband Inc. (NTRB)vs › | $79.74M | 49.29 | 25.94 | 25.30 | 23.23 |
| Citius Oncology, Inc. (CTOR)vs › | $79.96M | 11.25 | 16.63 | 16.63 | 16.63 |
| Outset Medical, Inc. (OM)vs › | $75.54M | 0.64 | 0.78 | 0.93 | 5.51 |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $80.90M | N/A | N/A | N/A | N/A |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-14 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-10 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
